AI-supported mammography screening results in fewer aggressive and advanced breast cancersAI-supported mammography screening results in fewer aggressive and advanced breast cancers
Artificial intelligence (AI)-supported mammography identifies more cancers during screening and reduces the rate of breast cancer diagnosis by 12% in the years following, finds the first randomized controlled trial of its kind. The trial involved over 100,000 Swedish women, and its results are published in The Lancet.
AI use in breast cancer screening cuts rate of later diagnosis by 12%, study findsAI use in breast cancer screening cuts rate of later diagnosis by 12%, study finds
Swedish study of 100,000 women found higher rate of early detection, suggesting potential to support radiologistsThe use of artificial intelligence in breast cancer screening reduces the rate of a cancer diagnosis by 12% in subsequent years and leads to a higher rate of early detection, according to the first trial of its kind.Researchers said the study was the largest to date looking at AI use in cancer screening. It involved 100,000 women in Sweden who were part of mammography screening and were randomly assigned to either AI-supported screening or to a standard reading by two radiologists between April 2021 and December 2022. Continue reading…
Amputation Risk in Diabetes Drops With GLP-1 Drugs, Study SuggestsAmputation Risk in Diabetes Drops With GLP-1 Drugs, Study Suggests
(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed. Among 17,288 patients, new… (MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major Read More
There Are Many Types of Obesity, Says This GLP-1 ExpertThere Are Many Types of Obesity, Says This GLP-1 Expert
A renowned physician-scientist says treatment is not one-size-fits-all. A renowned physician-scientist says treatment is not one-size-fits-all.
GLP-1 Drugs and Liver Complications; Tracking Endoscopists’ Eyes; Peppermint for IBSGLP-1 Drugs and Liver Complications; Tracking Endoscopists’ Eyes; Peppermint for IBS
(MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) in type 2 diabetes patients compared with other glucose-lowering therapies, a systematic… (MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) Read More
Blood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancerBlood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer. The study uncovers a novel role for soluble E-cadherin (sEcad) in promoting tumor invasion while resisting cancer cell death and triggering brain inflammation via the CXCR2 signaling pathway.
Minimally invasive test offers new insights into breast cancer spread and immune responseMinimally invasive test offers new insights into breast cancer spread and immune response
New research led by King’s College London suggests that a simple test already used in clinics could provide valuable additional insights into how the body’s immune system responds to cancer, without requiring any extra procedures for patients.
‘Night Owls’ and Heart Risks; AI Grades Med School Exams; GLP-1 Drug Patients Sue’Night Owls’ and Heart Risks; AI Grades Med School Exams; GLP-1 Drug Patients Sue
(MedPage Today) — Note that some links may require registration or subscription. “Night owls” may be at higher cardiovascular disease, but it mostly comes down to their overall health behaviors, according to a U.K. Biobank cohort study. (Journal… (MedPage Today) — Note that some links may require registration or subscription. “Night owls” may be Read More
Palbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancerPalbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancer
1. This randomized controlled trial found that, in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer, the addition of palbociclib to standard therapy extended progression-free survival by more than one year. 2. Adverse events, most commonly neutropenia, were more frequent with palbociclib, though no deaths were determined to be related to the treatment. Evidence Rating Level:
The post Palbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancer first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
Research improves risk assessment for hereditary breast cancerResearch improves risk assessment for hereditary breast cancer
Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer. By identifying which mutations affect the function of PALB2, doctors can now assess much more accurately which mutations are linked to an increased risk of breast cancer.